Cargando…

Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases

This paper presents a summary of reported cases of Serious Adverse Events (SAEs) following treatment with Mectizan(® )(ivermectin, Merck, Sharpe & Dohme) in onchocerciasis mass treatment programs from January 1, 1989 to December 31, 2001 through a passive surveillance system. A total of 207 SAE...

Descripción completa

Detalles Bibliográficos
Autor principal:	Twum-Danso, Nana AY
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2147655/ https://www.ncbi.nlm.nih.gov/pubmed/14975060 http://dx.doi.org/10.1186/1475-2883-2-S1-S3

Ejemplares similares

Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future
por: Twum-Danso, Nana AY
Publicado: (2003)

Serious Neurological Adverse Events after Ivermectin—Do They Occur beyond the Indication of Onchocerciasis?
por: Chandler, Rebecca E.
Publicado: (2018)

Programmatic and Communication Issues in Relation to Serious Adverse Events Following Ivermectin Treatment in areas Co-endemic for Onchocerciasis and Loiasis
por: Haselow, Nancy J, et al.
Publicado: (2003)

Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon
por: Boussinesq, Michel, et al.
Publicado: (2003)

Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
por: Awadzi, Kwablah
Publicado: (2003)

Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.
por: Mackenzie, Charles D, et al.
Publicado: (2003)

Report of a Scientific Working Group on Serious Adverse Events following Mectizan(® ) treatment of onchocerciasis in Loa loa endemic areas
Publicado: (2003)

Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin
por: Wilson, Nana O., et al.
Publicado: (2016)

Overview: Report of a Scientific Working Group on Serious Adverse Events following Mectizan(®) treatment of onchocerciasis in Loa loa endemic areas.
por: Duke, Brian OL
Publicado: (2003)

Would ivermectin for malaria control be beneficial in onchocerciasis-endemic regions?
por: Siewe Fodjo, Joseph Nelson, et al.
Publicado: (2019)

The geographic distribution of onchocerciasis in the 20 participating countries of the African Programme for Onchocerciasis Control: (1) priority areas for ivermectin treatment
por: Noma, Mounkaila, et al.
Publicado: (2014)

Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa
por: Chesnais, Cédric B., et al.
Publicado: (2020)

Adherence to ivermectin is more associated with perceptions of community directed treatment with ivermectin organization than with onchocerciasis beliefs
por: Dissak-Delon, Fanny Nadia, et al.
Publicado: (2017)

Comparison of Repeated Doses of Ivermectin Versus Ivermectin Plus Albendazole for the Treatment of Onchocerciasis: A Randomized, Open-label, Clinical Trial
por: Batsa Debrah, Linda, et al.
Publicado: (2020)

Factors associated with compliance with community directed treatment with ivermectin for onchocerciasis control in Southwestern Ethiopia
por: Yirga, Daniel, et al.
Publicado: (2010)

Impact of Six Years Community Directed Treatment with Ivermectin in the Control of Onchocerciasis, Western Ethiopia
por: Samuel, Abdi, et al.
Publicado: (2016)

Implementation Challenges of Community Directed Treatment with Ivermectin Program for Control of Onchocerciasis in Ulanga, Tanzania
por: Mushi, Vivian
Publicado: (2021)

Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria
por: Brieger, William R, et al.
Publicado: (2011)

Sustainable Control of Onchocerciasis: Ocular Pathology in Onchocerciasis Patients Treated Annually with Ivermectin for 23 Years: A Cohort Study
por: Banla, Méba, et al.
Publicado: (2014)

The Cost of Annual versus Biannual Community-Directed Treatment of Onchocerciasis with Ivermectin: Ghana as a Case Study
por: Turner, Hugo C., et al.
Publicado: (2013)

Audit of the community-directed treatment with ivermectin (CDTI) for onchocerciasis and factors associated with adherence in three regions of Cameroon
por: Kamga, Guy-Roger, et al.
Publicado: (2018)

The impact of ivermectin on onchocerciasis in villages co-endemic for lymphatic filariasis in an area of onchocerciasis recrudescence in Burkina Faso
por: Nikièma, Achille S., et al.
Publicado: (2021)

Primary motives for demand of ivermectin drug in mass distribution programmes to control onchocerciasis
por: Abanobi, Okwuoma, et al.
Publicado: (2011)

Predictors of compliance with community-directed treatment with ivermectin for onchocerciasis control in Kabo area, southwestern Ethiopia
por: Endale, Adugna, et al.
Publicado: (2015)

Impact of long-term treatment of onchocerciasis with ivermectin in Ecuador: potential for elimination of infection
por: Vieira, Juan Carlos, et al.
Publicado: (2007)

Uncertainty Surrounding Projections of the Long-Term Impact of Ivermectin Treatment on Human Onchocerciasis
por: Turner, Hugo C., et al.
Publicado: (2013)

Elimination of African Onchocerciasis: Modeling the Impact of Increasing the Frequency of Ivermectin Mass Treatment
por: Coffeng, Luc E., et al.
Publicado: (2014)

Drawing and interpreting data: Children's impressions of onchocerciasis and community-directed treatment with ivermectin (CDTI) in four onchocerciasis endemic countries in Africa
por: Amuyunzu-Nyamongo, Mary, et al.
Publicado: (2011)

Collateral Impact of Community-Directed Treatment with Ivermectin (CDTI) for Onchocerciasis on Parasitological Indicators of Loa loa Infection
por: Nana-Djeunga, Hugues C., et al.
Publicado: (2020)

Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control
por: Tekle, Afework Hailemariam, et al.
Publicado: (2012)

Determinants of community-led ivermectin treatment adherence for onchocerciasis control in Western Ethiopia: a case-control study
por: Ayalew, Fikadu, et al.
Publicado: (2020)

Ivermectin Treatment in Patients With Onchocerciasis-Associated Epilepsy: Protocol of a Randomized Clinical Trial
por: Colebunders, Robert, et al.
Publicado: (2017)

Reaching the London Declaration on Neglected Tropical Diseases Goals for Onchocerciasis: An Economic Evaluation of Increasing the Frequency of Ivermectin Treatment in Africa
por: Turner, Hugo C., et al.
Publicado: (2014)

The Mectizan(® )Donation Program – highlights from 2005
por: Alleman, Mary M, et al.
Publicado: (2006)

Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa
por: Borsboom, Gerard JJM, et al.
Publicado: (2003)

Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside
por: Assmus, Frauke, et al.
Publicado: (2022)

Persistence of onchocerciasis in villages in Enugu and Ogun states in Nigeria following many rounds of mass distribution of ivermectin
por: Ekpo, Uwem F., et al.
Publicado: (2022)

Impact of repeated ivermectin treatments against onchocerciasis on the transmission of loiasis: an entomologic evaluation in central Cameroon
por: Kouam, Marc K, et al.
Publicado: (2013)

Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis
por: Stolk, Wilma A., et al.
Publicado: (2015)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5iv1rmnsp22u327rlq9ael8m06